Multiple myeloma ISS stage
Multiple myeloma ISS stage - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
Open the Multiple myeloma ISS stage → Runs in your browser. No signup, no tracking.
What this is
Multiple myeloma ISS stage is one of 230 deterministic tools in Sophie Well's Clinical Scoring & Risk group. Multiple myeloma ISS stage - a deterministic tool in Sophie Well's Clinical Scoring & Risk group.
When to use it
Use this tool when you need a quick, citable reference. Every calculation runs entirely in your browser - no inputs leave your device, no account is required, no AI is involved. The site enforces a strict Content Security Policy and ships no analytics or third-party CDN.
References
Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420. Read the source ↗
Worked example: Multiple myeloma ISS stage I (beta2-microglobulin 3.2 mg/L, albumin 4 g/dL; beta2-microglobulin < 3.5 and albumin >= 3.5) -- median overall survival ~62 months in the 2005 derivation cohort.
Sophie Well is a reference and educational tool. Not medical, legal, or financial advice. Does not replace clinician judgment, professional billing review, or legal counsel.